Lugo, 30 de septiembre de 2025. – AMSbiopharma, laboratorio lucense perteneciente al Grupo AMSlab, ha presentado esta mañana en un evento online los resultados de su Plan de Innovación, desarrollado a lo largo de los últimos 18 meses con el apoyo de la Axencia Galega de Innovación (GAIN) a través del programa InnovaPeme 2024. La iniciativa permitirá reforzar la posición competitiva de la empresa en el sector biofarmacéutico global, mediante la puesta en valor de la innovación intangible, la implementación de nuevos protocolos de calidad, el fomento del intraemprendimiento y la expansión internacional.
To ensure the plan’s success, the company has also strengthened its team by adding new, highly qualified personnel, selected according to strict criteria of technical and professional excellence.
During the plan’s implementation, AMSbiopharma has launched research projects and agreements with public and private entities that have allowed it to diversify its activities, enhance its staff’s expertise, and open new lines of work. These partnerships have strengthened the company’s competitiveness and generated key technical knowledge to address the challenges of a constantly evolving sector.
Continuous improvement in quality and technology
The company is driving continuous improvement of its quality protocols to ensure the highest safety, efficacy, and reliability of its analytical processes. Furthermore, technological innovations in data encryption and control have been incorporated, enhancing the traceability and transparency of its processes. These advancements are complemented by the commissioning of new facilities designed to strengthen AMSbiopharma’s capacity to develop high-value analytical services.
The Innovation Plan has strengthened the entrepreneurial culture within the company. Thanks to synergies with the different companies in the AMSlab Group, knowledge sharing has been enhanced and initiatives have been promoted in which employees themselves have taken an active role in the development of innovative projects.
Internationalization has been another pillar of the plan. AMSbiopharma has deployed market research strategies in new countries, with notable milestones such as the trade mission to North Carolina. This trip facilitated the establishment of strategic partnerships with research centers and opened new avenues of cooperation aimed at positioning Galicia as a key player in the international biotechnology sector.
A commitment to Galician biotechnology
With the completion of this plan, AMSbiopharma consolidates its commitment to technological innovation and continuous process improvement, reaffirming its role as a driving force in the biotechnology sector in Lugo and Galicia. “This project represents a step forward for AMSbiopharma on its path toward differentiation, internationalization, and innovation. Thanks to this investment, we are increasing our competitiveness by offering high-value services to the biopharmaceutical sector,” the company’s management emphasized.
AMSbiopharma’s Innovation Plan has been subsidized by GAIN, through the InnovaPeme 2024 business aid program.
Bioga Press Office. 679.486.961.
